Back to List

News

Jan 06, 2015
Tobira Therapeutics
Tobira Therapeutics' Cenicriviroc Granted Fast Track Designation by the FDA for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients with Liver Fibrosis